Purpose: Chemoresistance in triple-negative breast cancer (TNBC) is associated with the
activation of a survival mechanism orchestrated by the endoplasmic reticulum (EnR) stress …

Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …

Simple Summary Triple Negative Breast Cancer represents a cancer type with an unmet
clinical need. This type of breast cancer presents the worse clinical outcome due to its …

Triple-negative breast cancer (TNBC) is one of the deadliest subtypes of breast cancer (BC)
for its high aggressiveness, heterogeneity, and hypoxic nature. Based on biological and …

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers
characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 …

Triple-negative breast cancer (TNBC) is characterized by a lack of expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 …

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer
which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby …

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular
subtyping may result in improved diagnostic precision and targeted therapies. Our previous …

Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …